Lees Pharmaceutical Holdings Stock Return On Asset
| LPCUFDelisted Stock | USD 0.0001 0.00 0.00% |
Lees Pharmaceutical Holdings fundamentals help investors to digest information that contributes to Lees Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Lees Pink Sheet. The fundamental analysis module provides a way to measure Lees Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lees Pharmaceutical pink sheet.
Lees |
Lees Pharmaceutical Holdings Company Return On Asset Analysis
Lees Pharmaceutical's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lees Pharmaceutical Return On Asset | 0.0591 |
Most of Lees Pharmaceutical's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lees Pharmaceutical Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Lees Pharmaceutical Holdings has a Return On Asset of 0.0591. This is 100.68% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is 142.21% lower than that of the firm.
Lees Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lees Pharmaceutical's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Lees Pharmaceutical could also be used in its relative valuation, which is a method of valuing Lees Pharmaceutical by comparing valuation metrics of similar companies.Lees Pharmaceutical is currently under evaluation in return on asset category among its peers.
Lees Fundamentals
| Return On Equity | -0.0531 | |||
| Return On Asset | 0.0591 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (1.58) % | |||
| Current Valuation | 123.64 M | |||
| Shares Outstanding | 588.84 M | |||
| Shares Owned By Insiders | 63.62 % | |||
| Shares Owned By Institutions | 6.36 % | |||
| Price To Book | 0.0002 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 1.27 B | |||
| Gross Profit | 806.28 M | |||
| EBITDA | 1.98 B | |||
| Net Income | 1.99 B | |||
| Cash And Equivalents | 368.05 M | |||
| Cash Per Share | 0.62 X | |||
| Total Debt | 84.09 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 1.04 X | |||
| Book Value Per Share | 3.64 X | |||
| Cash Flow From Operations | 210.68 M | |||
| Number Of Employees | 1.32 K | |||
| Beta | 0.91 | |||
| Market Capitalization | 275.66 B | |||
| Total Asset | 3.64 B | |||
| Annual Yield | 52.23 % | |||
| Net Asset | 3.64 B | |||
| Last Dividend Paid | 0.041 |
About Lees Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lees Pharmaceutical Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lees Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lees Pharmaceutical Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Lees Pink Sheet
If you are still planning to invest in Lees Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lees Pharmaceutical's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |